Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues

Arturo López Castel¹, Masayuki Nakamori³, Stephanie Tomé¹,⁴, David Chitayat¹,²,⁵,⁶, Geneviève Gourdon⁴, Charles A. Thornton³ and Christopher E. Pearson¹,⁶,*

¹Genetics and Genome Biology and ²Department of Pediatrics, Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada M5G 1L7, ³Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA, ⁴Inserm U781, Hôpital Necker-Enfants Malades, Paris 75015, France, ⁵Department of Obstetrics and Gynecology, The Prenatal Diagnosis and Medical Genetics Program, Mount Sinai Hospital, Toronto, Ontario, Canada and ⁶Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada

Received August 17, 2010; Revised and Accepted September 27, 2010

Myotonic dystrophy (DM1) affects multiple organs, shows age-dependent progression and is caused by CTG expansions at the DM1 locus. We determined the DM1 CpG methylation profile and CTG length in tissues from DM1 foetuses, DM1 adults, non-affected individuals and transgenic DM1 mice. Analysis included CTCF binding sites upstream and downstream of the CTG tract, as methylation-sensitive CTCF binding affects chromatinization and transcription of the DM1 locus. In humans, in a given foetus, expansions were largest in heart and smallest in liver, differing by 40–400 repeats; in adults, the largest expansions were in heart and cerebral cortex and smallest in cerebellum, differing by up to 5770 repeats in the same individual. Abnormal methylation was specific to the mutant allele. In DM1 adults, heart, liver and cortex showed high-to-moderate methylation levels, whereas cerebellum, kidney and skeletal muscle were devoid of methylation. Methylation decreased between foetuses and adults. Contrary to previous findings, methylation was not restricted to individuals with congenital DM1. The expanded repeat demarcates an abrupt boundary of methylation. Upstream sequences, including the CTCF site, were methylated, whereas the repeat itself and downstream sequences were not. In DM1 mice, expansion-, tissue- and age-specific methylation patterns were similar but not identical to those in DM1 individuals; notably in mice, methylation was present up- and downstream of the repeat, but greater upstream. Thus, in humans, the CpG-free expanded CTG repeat appears to maintain a highly polarized pattern of CpG methylation at the DM1 locus, which varies markedly with age and tissues.

INTRODUCTION

Myotonic dystrophy type 1 [DM1 (MIM 160900)] is an inherited multisystemic disorder with a highly variable clinical presentation (1,2). Multiple organs are affected, with muscle weakness and wasting, myotonia, cardiac conduction defects, cataracts and neuropsychological impairment being some of the most characteristic clinical features. The inheritance pattern shows an earlier age of onset and more severe symptoms in successive generations. The spectrum of DM1 ranges from mild, late-onset symptoms to severe disease in infancy, with severity and age of onset roughly correlating inversely with the increasing size of the (CTG)n expansion.

The molecular basis of DM1 involves an expansion, always larger than 50 repeats but able to reach thousands of units, of a CTG tract within the 3’untranslated region (UTR) of the DMPK gene (3). At least two mechanisms of disease pathogenesis are thought to contribute to DM1. First, the expression
of RNA with an expanded CUG repeat alters the activity of RNA splicing factors, resulting in mis-regulated alternative splicing of many different genes (4). Secondly, the expanded repeat can affect its own expression, that of its anti-sense transcript and genes upstream and downstream of DMPK (5–12). Both modes of pathogenesis are affected by CTG expansion size, and the latter is also linked to epigenetic modifications of the DM1 locus. The DM1 CTG repeat is located in a gene-rich region of the genome (13) and is embedded in a large 3.5 kb CpG island (Fig. 1A and B) (14). In addition to its presence in the 3′-UTR of the DMPK gene, the CTG repeat is in the promoter of the downstream SIX5 gene. The expanded CTG repeat modifies the transcription of SIX5 (5–7,10) and DMWD (13,15). This modified allelic expression of DM1 locus genes can vary between tissues (7,8,16–20), a phenomenon thought to be mediated by altered chromatin packaging (10,21,22). In addition, transcription across the anti-sense strand of the DMPK gene can also be modified by the expansion, a phenomenon that is regulated by binding of the chromatin insulator CTCF to sequence motifs adjacent to the DM1 CTG tract (9,11). These allelic alterations in gene expression are thought to contribute to the varied symptoms of DM1 (23–25). Chromatin packaging is altered at the DM1 locus with expanded DM1 repeats compared with the corresponding wild-type allele. Strong nucleosome positioning upon the expanded CTG repeats (26) and loss of a DNasel and nuclease hypersensitive site some 700 bp downstream of the repeat (9,10,27) suggested a compact chromatin packaging. Histone marks associated with heterochromatic conformation were present in a DM1 cell line (11). This DM1 chromatin packaging is thought to be mediated by CpG methylation-sensitive binding of the chromatin insulator CTCF proximal to the CTG repeat. Other disease-associated repeat expansions and contractions such as fragile X syndrome [FRAXA (MIM 300624)], Friedreich ataxia [FRDA (MIM 229300)] and facioscapulohumeral muscular dystrophy [FSHD (MIM 158900)] are also known to have differential CpG methylation and chromatin packaging which affects gene expression (reviewed in 21,22).

DM1 patients display high levels of CTG instability between different tissues of the same individual, with large inter-tissue CTG length differences (28–35). This somatic instability is detectable as early as 13–16 weeks during foetal development and continues following birth to varying degrees in different tissues (28,30,36–40). Although the significance of somatic repeat heterogeneity to disease is unclear, ongoing expansions have been proposed to exacerbate DM1 symptoms as they are usually largest in clinically important tissues such as skeletal muscle, heart and brain (36,40). Recent evidence suggests that CpG methylation and CTCF binding may contribute to CTG/CAG repeat instability (41–45). However, it is unknown whether and how CpG methylation and CTG length heterogeneity may correlate between tissues and developmental periods. Although instability shows development- and tissue-specific patterns, an analysis of both foetal and adult tissues in a single study has not been performed. The use of newly developed methods will allow for improved higher-resolution analyses of somatic CTG instability profiles (46) compared with studies performed over 15 years ago using low-resolution methods (28,30,36–40).

The dynamic regulation of CpG methylation in tissue- and development-specific manners and its important roles in controlling cellular processes (47–52) make this epigenetic mark worthy of analysis at the DM1 locus. However, information of the CpG methylation status at the DM1 locus is very limited. Only two reports on CpG methylation at the DM1 locus have been published (summarized in Supplementary Material, Fig. S1). Using methylation-sensitive restriction analysis, both reports observed constitutive methylation in all individuals tested [non-affected, classical DM1 and congenital DM1 (CDM)]. Shaw et al. (53) found methylation (~3300–8700 bp) upstream of the CTG tract. Steinbach et al. (54) also found methylation (1159–1232 bp) upstream of the repeat tract. These sites appear to coincide with recently observed methylation in non-affected cells (Supplementary Material, Fig. S1) (52). Shaw et al. (53) reported no methylation differences between unaffected individuals and either classical DM1 or CDM patients. In contrast, Steinbach et al. (54) observed complete methylation at numerous HpaII and HhaI upstream sites, extending up to a single SacII site just upstream of the CTG repeat (as close as 42 bp) for patients with large CTG expansions [up to (CTG)1833 repeats] and juvenile onset or congenital disease. In the same study, classical DM1 adult onset DNAs with similar repeat lengths did not show the same methylation. Both studies were limited, in that methylation was assessed primarily in leukocytes of post-natal individuals and did not take into account potential tissue-specific or development-specific differences. Furthermore, both studies only assessed methylation upstream of the repeat and used methyl-sensitive restriction digestion, which misses many CpG sites and is not quantitative.

Various points indicate that a deeper appreciation of the methylation status at the DM1 locus is needed: considering (i) the tissue specificity of DM1 disease symptoms; (ii) the tissue-, development- and age-specific somatic instability of the CTG repeat; (iii) the many DM1 region transcripts (sense and anti-sense) whose expression may be affected by methylation; (iv) the regulation of DNA methylation known to be dynamically modulated; make it interesting to learn the methylation status in a variety of tissues from DM1 individuals of various ages and developmental stages and (v) recent evidence suggests that high levels of non-CpG cytosine methylation can occur predominantly at CAG and CTG sequences (52) and such methylation has been reported at non-expanded repeats of certain disease loci (55). The methylation status of the expanded repeat and adjacent sequences in patient tissues is unknown.

We characterized at high resolution the CpG methylation profile of the DM1 locus, focusing on regions close to the CTG repeat (Fig. 1C and D). Methylation profiles using bisulphite sequencing were determined at each CpG site upstream and downstream of the CTG repeat including the two DM1 CTCF binding sites (9). Non-CpG methylation of the CTG/CAG repeat was assessed using a newly developed restriction assay. Both methylation and repeat length were assessed in various tissues and developmental windows in several individuals (foetuses and adult autopsies) and in transgenic DM1 mice. Tissue-, age- and DNA region-specific variations in CpG methylation were observed only in tissues with CTG expansions. Contrary to previous findings
Figure 1. Detailed genomic and sequence location of the DNA regions analysed for CpG methylation. (A) View of the gene-enriched region in human chromosome 19 where the DMPK gene and the CTG repeat tract are enclosed. Pink shadow shows the human region (~45 kb) single integrated in the DM1 transgenic mouse genomes. (B) A more detailed view of the ~45 kb region that includes the DMPK gene (20 or more than 300 CTG repeats in mice DM20-949 and DM300-328, respectively) and neighbouring genes. CpG islands through this region are marked in green, as derived from the UCSC Genome Browser (104). The regions previously analysed for methylation (black bars) (53,54) and the DNAase hypersensitive site detected upstream (yellow triangle) (27), coincident with the anti-sense transcription initiation reported in the DM1 locus (11), are also indicated. (C) The DMPK regions analysed by bisulphite sequencing PCR, located proximal and distal to the CTG repeat tract, are shown, as well as the CTCF binding sites 1 and 2 (grey shadows) (9). (D) DMPK sequence analysed by bisulphite sequencing PCR. PCR primers location, CTCF binding sites, CpG sites and HpaII, HhaI and SacII methylation-sensitive sites are indicated. For all sections, the CTG repeat is shown in red. Cctcf1 and cctcf2 primer sets for hemi-nested PCR amplification after DNA bisulphite treatment are shown.
RESULTS

CTG length heterogeneity in DM1 patient tissues

Various post mortem tissues from human foetal, adult DM1 patients and non-DM1 controls (Table 1) were collected to assess the DNA methylation status and to determine the inter- and intra-tissue CTG length variations. For repeat length analysis, we used a high-resolution method [locked nucleic acid (LNA) probe-Southern] that takes advantage of the increased electrophoretic resolution of DM1 restriction fragments having a minimum of non-repetitive flanking sequences, reduced background hybridization and a repeat-specific LNA probe (46). Representative Southern blots are shown in Figure 2, and CTG sizes for each individual are summarized in Table 1. Short DM1 alleles were polymerase chain reaction (PCR)-amplified and sequenced.

Of the foetal tissues assessed, the largest expansions often arose in heart and muscle, whereas the smallest expansions were in liver (Fig. 2A and Table 1; Supplementary Material, Fig. S2). Intra- and inter-tissue repeat heterogeneity was not apparent for the foetus with the shortest gestational age and smallest expansion (DC-FEDM3, 14 weeks, 1600 CTG repeats). Only two tissues from this foetus were available for analysis (heart and skeletal muscle). In DC-FEDM2 and DC-FEDM1, foetuses with larger repeats or longer gestation, inter-tissue differences of 120 and 40 repeats were detected between heart and skeletal muscle, respectively (Table 1). Overall, the greatest inter-tissue CTG length differences in foetal samples were 400 and 240 repeats for foetuses DC-FEDM2 (19 weeks, 3820 CTG repeats) and DC-FEDM1 (14 weeks, 2660 CTG repeats), respectively. The intra-tissue repeat length heterogeneity was limited in all foetuses, as evident by the relatively distinct bands. These modest levels of CTG instability in foetuses of 14–19 weeks are consistent with previous studies, suggesting that ∼13 weeks is the developmental window when somatic instability starts to become apparent (35).

Adult DM1 tissues displayed large inter-tissue CTG length variations, and the intra-tissue length heterogeneity was also extensive (Fig. 2B and Table 1; Supplementary Material, Fig. S3). The greatest length range was in the cerebral cortex, followed by liver and skeletal muscle, with length heterogeneity spanning as many as 2800 repeats (Table 1, Supplementary Material, Fig. S3). In adult tissues, the expansions were consistently largest in the heart and cerebral cortex (up to 6550 repeats), whereas the smallest expansions were in the cerebellum (Supplementary Material, Fig. S2). The greatest inter-tissue CTG length differences were 5770, 5240, 4900, 4890 and 1700 repeat units, for patients UR-ADM8, UR-ADM5, UR-ADM9, UR-ADM6 and UR-UDM4, respectively. The larger inter-tissue CTG length differences and intra-tissue CTG length heterogeneity observed in adult tissues are consistent with previously reported active instability occurring over the age of the DM1 individual (35–37).

Together, the foetal and adult samples support the existence of ongoing somatic CTG instability with age, as the adult samples displayed greater degrees of both inter-tissue and intra-tissue length heterogeneity. Expansion patterns between tissues were different for foetal and DM1 adults, suggesting tissues-specific rates or times of expansion. For example, comparing the foetal with adult normalized inter-tissue length differences, it is apparent that in foetuses, the liver incurs fewer expansions than heart, brain or muscle, whereas in adults, the liver has incurred similar expansions as heart, brain (cortex) and muscle (Supplementary Material, Fig. S2). Other evidence suggests that CTG expansions in the DM1 muscle occur more rapidly earlier than later in life (38). Only the expanded, mutant DM1 allele showed severe length variations. The non-expanded DM1 CTG repeat did not change dramatically in any of the DM1 foetal or adult tissues and did not show variation in control non-DM1 foetal or adult tissues (Table 1). We observed some minor products with CTG lengths just greater by a few repeat units compared with the non-expanded allele in cortex, skeletal muscle and cerebellum in the UR-ADM9 adult sample (juvenile DM1). Such limited DM1 CTG size fluctuations have been reported previously in somatic tissues of non-expanded alleles (muscle and heart) (56,57). Thus, CTG instability of the expanded allele was tissue-specific with age-specific variations.

CpG methylation in DM1 patient tissues

We focused our methylation analysis upon regions immediately flanking unstable CTG tract, as these include the CTCF binding sites, demonstrated to epigenetically regulate expression of the DM1 locus (5,9,11). This region includes 18 CpG sites upstream and 11 downstream from the CTG repeat, respectively (Fig. 1). Only minimal methylation was present in non-DM1 foetal and adult tissue samples (Figs 3 and 4, top panels). In contrast, each of three DM1 foetuses that we examined showed prominent methylation (Fig. 3, bottom panel). Strikingly, the location of the methylation was highly polarized (methylation was present at every CpG site analysed upstream of the CTG repeat), whereas methylation downstream of the repeat was absent in two DM1 foetuses and sparse in the third (Fig. 3, bottom panel). The presence of methylation upstream but not downstream of the expanded repeat suggested that the repeat may block methylation progression. However, that the CTG repeat itself may harbour non-CpG methylation could not be excluded. The presence of non-CpG methylation was assessed through the expanded CTG/CAG repeat (Fig. 5) to better demarcate the borders of aberrant methylation. High levels of non-CpG methylation in the expanded repeat were not detected in foetal samples that showed high levels of aberrant CpG
Table 1. Human samples analysed

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age of examination</th>
<th>Gender</th>
<th>Disease status</th>
<th>Parental transmission</th>
<th>Source</th>
<th>CTG repeat alleles (length)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Short Expanded (peak if smear)</td>
</tr>
<tr>
<td>DC-FEFX1</td>
<td>Foetus: 14 weeks</td>
<td>Male</td>
<td>Non-DM1</td>
<td>—</td>
<td>Skeletal muscle</td>
<td>13/13 —</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>—</td>
</tr>
<tr>
<td>DC-FEDM1a</td>
<td>Foetus: 14 weeks</td>
<td>Male</td>
<td>(DM1/CDM)</td>
<td>Maternal (5/800)</td>
<td>Heart</td>
<td>11 2660</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreas</td>
<td>2660</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
<td>2620</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skin</td>
<td>2620</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brain</td>
<td>2580</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>2420</td>
</tr>
<tr>
<td>DC-FEDM2a</td>
<td>Foetus: 18–19 weeks</td>
<td>Male</td>
<td>(DM1/CDM)</td>
<td>n.d.</td>
<td>Heart</td>
<td>11 3820</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
<td>3700</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brain</td>
<td>3530</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>3420</td>
</tr>
<tr>
<td>ADN1</td>
<td>Adult: 54 years</td>
<td>Male</td>
<td>Non-DM1</td>
<td>—</td>
<td>Skeletal muscle</td>
<td>11/14 —</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreas</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brain</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>—</td>
</tr>
<tr>
<td>UR-ADM9a</td>
<td>Adult: 44 years</td>
<td>Female</td>
<td>Juvenile DM1</td>
<td>n.d.</td>
<td>Heart</td>
<td>12 4100–5300 (4600), 6000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>4200–4600 (4500)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skeletal muscle</td>
<td>3700–4300 (4200)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>4000–5500 (4900)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebellum</td>
<td>1100–1500 (1200), 3800–4600 (—)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>3700–4300 (4200)</td>
</tr>
<tr>
<td>UR-ADM6a</td>
<td>Adult: 47 years</td>
<td>Male</td>
<td>Classical DM1</td>
<td>n.d.</td>
<td>Heart</td>
<td>5 3700–4300 (4200)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>2800–5300 (4800)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>3900–4900 (4500)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebellum</td>
<td>3500–5300 (5200)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>410, 580</td>
</tr>
<tr>
<td>UR-ADM4a</td>
<td>Adult: 50 years</td>
<td>Female</td>
<td>Classical DM1</td>
<td>n.d.</td>
<td>Heart</td>
<td>10 4900, 6300</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skeletal muscle</td>
<td>4600–5400 (5100)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>4200–5300 (4900)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skeletal muscle</td>
<td>3300–4400 (3900), 5300–6100 (—)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>4500–4900 (4800)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>2200–5500 (4900)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebellum</td>
<td>330, 440, 4200–4500 (—)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart</td>
<td>5100–6550 (6000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
<td>4900–5600 (5300)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
<td>4600–5400 (5000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreas</td>
<td>4400–5100 (4600)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cortex</td>
<td>2900–5700 (5400)</td>
</tr>
<tr>
<td>UR-ADM5a</td>
<td>Adult: 55 years</td>
<td>Male</td>
<td>Classical DM1</td>
<td>n.d.</td>
<td>Heart</td>
<td>4 3900–4400 (4100)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skeletal muscle</td>
<td>1310</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebellum</td>
<td>1310</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood</td>
<td>5 80</td>
</tr>
<tr>
<td>UR-ADM3</td>
<td>Adult: 80 years</td>
<td>Male</td>
<td>Minimal DM1</td>
<td>n.d.</td>
<td>Grey matter</td>
<td>177</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>White matter</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood</td>
<td>5 80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grey matter</td>
<td>177</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell line</td>
<td>—</td>
</tr>
<tr>
<td>DMRB993b,c</td>
<td>Adult: 12 years</td>
<td>Female</td>
<td>Congenital DM1</td>
<td>n.d.</td>
<td>Skin fibroblast</td>
<td>14 2973</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell line</td>
<td>—</td>
</tr>
<tr>
<td>94-916d</td>
<td>Adult: 54 years</td>
<td>Female</td>
<td>Classical DM1</td>
<td>Both parents</td>
<td>Blood</td>
<td>— 60/1000</td>
</tr>
<tr>
<td>99-423e</td>
<td>Adult: 18 years</td>
<td>Female</td>
<td>Assympt.</td>
<td>Both parents</td>
<td>Blood</td>
<td>— 85/90</td>
</tr>
<tr>
<td>06-2095d</td>
<td>Adult: 20 years</td>
<td>Female</td>
<td>Assympt.</td>
<td>Both parents</td>
<td>Blood</td>
<td>— 75/90</td>
</tr>
</tbody>
</table>

DM1 or CDM, not diagnosed DM1 form; assympt., asymptomatic; n.d., no data.

aLong expanded alleles sized by LNA-Southern approach (46).
b(—) Weak smear, no peak calculation.
cSee Krahe et al. (58) and Frisch et al. (10).
dSee Martorell et al. (60).
eSee Cobo et al. (59).
methylation upstream of the repeat (heart and brain in DC-FEDM2).

Although high levels of methylation were present in most foetal tissues, a few dramatic tissue-specific differences were also observed in DC-FEDM1, a foetus with early gestation. In contrast to highly methylated tissues, skeletal muscle and pancreas were not methylated in the same patient, suggesting DM1 tissue-specific methylation issues already in early disease developmental stages. Simultaneously, the high levels of methylation upstream of the CTG repeat are encompassing the CpG sites critical for CTCF binding in many foetal tissues.

Methylation was also assessed in adult post mortem tissues from four individuals with classical DM1 and one adult with juvenile-onset DM1. Once again, highly expanded CTG repeats in these samples were associated with abnormal methylation in every patient. Similar to foetal samples, the adult tissues exhibited a striking polarity, so that methylation was restricted to sites upstream of the expanded repeat. When compared with foetal sample, the overall levels of methylation in adult tissues were lower (compare Figs 3 and 4, bottom panels). Most adult DM1 tissues showed partial methylation (no presence of methylation in all CpG sites assessed) in the upstream region. Notably, methylation in DM1 adults did not consistently occur at specific CpG sites or show an obvious correlation with CTG expansion size. In general, the heart, cerebral cortex and liver often displayed more methylation, whereas the cerebellum and skeletal muscle displayed minimal levels of methylation. Methylation levels were less in adult tissues compared with matching tissues of foetuses.

Aberrant methylation is specific to the expanded DM1 allele

To test whether the methylation detected by bisulphite sequencing in DM1 samples was specific to the disease allele, we devised a methyl-specific multiplex PCR assay using the methylation-sensitive enzyme SacII, for which there is one proximal site (42 bp) upstream of the CTG tract (Fig. 6), the same SacII site assessed by Steinbach et al. (54). Our forward and reverse primers were placed on opposite sides of the CTG repeat and therefore were only capable of amplifying across the non-expanded CTG tract. One downstream and two upstream primers that did and did not cover the SacII site permitted determination of the methylation status of the SacII site in the non-expanded allele (Fig. 6A). Results revealed that in the absence of SacII digestion, two PCR products, both from the non-expanded allele, were evident. Successful SacII digestion, an indication of a non-methylated template, eliminated only the PCR product that encompassed the SacII site. Representative examples are shown in Figure 6B. Thus, the absence of methylation on
the non-expanded allele supports the conclusion that the high levels of CpG methylation detected by bisulphite sequencing originated from the expanded allele.

All of the DM1 foetal and DM1 adult tissues described earlier contained large CTG tract sizes with the shortest being more than 330 repeats (cerebellum) or more than 1600 in other tissues. A DM1 patient with a small CTG expansion of 80, 105 and 177 CTG repeats in the blood, cortex white matter and cortex grey matter (UR-ADM3, Table 1) displayed essentially no methylation in any of the CpG sites tested (Fig. 7), which contrasts with the high levels of methylation in the cortex of DM1 adults with larger expansions. It is unclear whether this absence of methylation indicates a CTG expansion size dependence upon becoming methylated or of methylation upon large expansion. Due to the limited availability of DM1 patient tissues with short expansions, we further addressed a possible association of methylation with CTG expansion size by assessing the methylation status of patient DNAs derived from either blood or cultured fibroblast cells. These included DM1 expansions of 133, 300 and 2973 repeats as well as DNAs from DM1 patients with homozygous expansions that are typically in the shorter range (60/1000; 85/90 and 75/90 repeats) (Fig. 7 and Table 1) (10,58–60). Only the largest expansion (CTG)2973 showed methylation, and this was present only in the upstream region. Together, these results support the suggestion that abnormal methylation correlates with large repeat expansions. Such a conclusion is consistent with the high levels of methylation in cells with expansions of (CTG)1833 repeats, but not in those with less than (CTG)1000 repeats (54). However, repeat length alone is unlikely to be the sole determinant of methylation, as many tissues with long repeat tracts did not show methylation, whereas other tissues from the same individual did (Fig. 4).

Figure 4. CpG methylation profiles from adult individuals. Top panel: non-DM1 adults analysed (cerebellum, skeletal muscle, cortex liver and heart); bottom panel: DM1 adults analysed including different tissue panels depending on the individual. DMPK alleles CTG repeat lengths (inside red box) and CTCF binding sites location (grey shadows) are indicated. White dots, CpG sites devoid of methylation; black dots, CpG sites with methylation presence.

Methylation of the human DM1 locus in transgenic mice

Transgenic organisms are powerful tools in the study of diseases caused by unstable repeats, and it is important to appreciate how these models reflect what is occurring in patients (Supplementary Material, Table S3 in reference 3). Towards such a comparison, we assessed CpG methylation in a well-characterized DM1 transgenic mouse model, which contains a single-copy integration of ~45 kb large segment of the human DM1 locus derived from a DM1 patient (Fig. 1A and B). Mice analysed...
harboured a short (DM20-949) or an expanded allele (DM300-328) with (CTG)20 or (CTG)300, respectively.

The same CpG regions adjacent to the repeat and a similar tissue set were assessed in the mice as in the human samples. Methylation of the human DM1 transgene in the DM1 mice showed similarities compared with the endogenous locus in human DM1 individuals: (i) both showed methylation exclusively on the expanded allele. No detectable or limited levels of methylation are present in the non-expanded line (DM20-949) (Fig. 8, top panel) contrasted with many methylated CpG sites in the expanded line (DM300-328) in the same tissues (Fig. 8, bottom panel); (ii) both humans and mice showed tissue-specific patterns of methylation. The DM300-328 cerebellum was devoid of methylation, whereas skeletal muscle and pancreas were highly methylated (Fig. 8, bottom panel) and (iii) both humans and mice showed less methylation in foetal/younger ages compared with adult ages. In young DM300-328 mice (2 months) and older (6 months), mice showed an age-dependent decrease of methylation levels (pancreas, heart and thymus in Fig. 9).

But humans and mice methylation also differed in: (i) mice showed age-dependent increases of methylation (the brain, for example); (ii) methylation patterns for a given tissue did not correlate exactly between species (compare Figs 4 and 8) and (3) unlike the human locus, which showed a polarized localization of methylation, the mice showed methylation both up- and downstream of the repeat with a preference for higher levels upstream (Fig. 10A). Thus, in some ways, the DM1 mouse model recapitulates methylation features of the DM1 locus in patients. However, variations between the DM1 mice and humans are evident, and these must be considered. A more detailed description of methylation in DM1 mice is given in Supplementary Material.
DISCUSSION

We mapped the sites of CpG methylation closest to the DM1 CTG repeat in a panel of human foetal and adult DM1 tissues. Methylation is present upstream of CTG expansions, but not downstream of the repeat or through the repeat itself, and not in non-expanded alleles. Upstream proximal methylation was specific to the expanded allele and present in classical and juvenile DM1 forms. Methylation is not uniform among tissues, not limited to tissues with the largest expansions, and is less conspicuous in older individuals.

Previous studies detected methylation far upstream (~3300–8700 and 1159–1232 bp) of the DM1 CTG repeat in all individuals analysed, including non-DM1 samples (Supplementary Material, Fig. S1) (53,54). High levels of methylation upstream and proximal to the repeat were also reported only in CDM (54). The most striking levels of methylation they observed were in an ‘exceptional’ dura matter cell line of a CDM foetus (P57F), which was compared with blood DNA of classical DM1 individuals assuming an absence of tissue specificity (54). Importantly, in our study, methylation was not limited to young, severely affected or CDM individuals, as previously suggested (54). A major difference between our approach and others is that previous studies used predominantly DNA from blood, whereas we studied DNA from various tissues. Methylation varied between tissues and between adults and foetuses, indicating that methylation status cannot be generalized from the analysis of a single tissue, time point in life or cell lineage. This confirms the suspicions of tissue specificity and developmental age, raised by Shaw et al. (53). Unlike Steinbach et al. (54), we do not observe a limitation of methylation to CDM individuals. Steinbach et al. (54) may not have detected methylation in classical DM1 individuals due to (i) the older DM1 patients they assessed may have lost or partially lost methylation, as observed in our aged DM1 adult patients, and (ii) the limited single-site methylation sensitivity of SacII restriction digestion analysis. We extended in high resolution the region analysed and delimited abnormal CpG methylation to the region upstream of the repeat region as CpG methylation downstream of the repeat is almost non-existent in human samples.

DM1 methylation spreading, polarity and boundary and polar elements

The presence of proximal methylation upstream of the expanded CTG repeat in DM1 patients, coupled with the far upstream methylation in non-affected individuals, raises the possibility that the mutant allele incurred methylation spreading from far upstream towards the expanded repeat. Such methylation spreading may have arisen due to the loss of a methylation boundary between these two regions. Such a phenomenon was recently reported for the FMR1 gene region, in which methylation far upstream in non-affected individuals was extended in FRAXA patient cells to encompass FMR1 promoter adjacent to the expanded CGG repeat (61). In FRAXA, FRAXE, FRAXF, FRAX10A, FRAX11B and FRAXA16A, the aberrant methylation included the expanded CGG repeat and downstream regions (62,63). If
methylation spreading occurred on the mutant DM1 alleles, it was limited to regions upstream of the CTG tract.

The abrupt demarcation of abnormal methylation at the DM1 locus suggests the presence of an insulator element acting as a barrier to block further spreading of methylation. The DM1 CTG repeat is flanked by CTCF binding sites, and CTCF binding at other genomic loci has been shown to serve as a boundary element between highly methylated and unmethylated genomic regions, defining regions of X-inactivation, genetic imprinting, and promoter activity (64–68). In those cases, the boundaries between methylated and unmethylated DNAs were defined by an enrichment of bound CTCF protein at an unmethylated CTCF binding site (65–69). However, at the DM1 locus, it is unlikely that the upstream CTCF-1 binding site can explain the abrupt boundary of methylation that we observed to occur at that point. This is unlikely because the methylation extends over and beyond the CTCF-1 binding site, right up to the 5′-end of the CTG tract. This methylation of the CTCF-1 binding site would be expected to abrogate CTCF binding, as has been observed by loss of in vitro binding (9), loss of chromatin immunoprecipitation and loss of in vivo footprints at the CTCF-1 site in DM1 cells (9,11,54). Thus, if the upstream CTCF-1 site is not the boundary element, this leaves either the downstream CTCF-2 binding site, which remains unmethylated in all cases, or the expanded CTG tract, which may serve as the boundary element. It is noteworthy that the expanded CTG repeat itself has been demonstrated to act as an insulator element by blocking transcription enhancer activity (9), and expanded CTG repeats in the absence of CTCF binding sites exhibit variation of expression of linked genes (70). Furthermore, the expanded DM1 CTG repeat constitutes an extended region (several kilobases) devoid of CpG dinucleotides, thereby interrupting and dividing the large 3.5 kb CpG island of the DM1 locus, which contrasts with the expanded CpG-containing CGG repeats in disease-linked rare fragile site syndromes. Interestingly, the aberrant DM1 methylation does not extend from the flank into the expanded CTG repeat; such an observation would be consistent with the inability of pre-existing CpG methylation to stimulate non-CpG methylation (71). Based on the demonstration that CAG repeats but not CGG repeats can stall the methyltransferase DNMT1 (72,73), we speculate that the CpG-free expanded CTG tract may insulate against CpG methylation spreading to downstream regions. Alternatively, the expanded repeat may act as a nidus, signalling abnormal polarized methylation.

Other instances of polarized elements relative to the DM1 CTG repeat have been reported. Chromatin packaging is altered in a polarized manner at the mutant DM1 locus with the loss of a DNase I and nuclease hypersensitive site some 700 bp downstream of the repeat (9,10,27). Some expanded DM1 repeats contain non-CTG interruptions, which only occurred at the 3′-end of the CTG repeat tract (74,75). Repeat tracts bearing these interruptions displayed unique inter-generational instability. Recently, the replication origin that replicates the expanded DM1 repeat in transgenic mice was localized to the region downstream of the repeat (45). The polar arrangement of CpG methylation, chromatin modifications, non-CTG interruptions and replication origins is interesting. Future studies will reveal if there is overlap in the regulation of these polarized elements at the DM1 locus.

### DM1 methylation dynamics

The DM1 disease-associated methylation appeared to depend on age. The density of methylation upstream of the expanded DM1 CTG repeat tracts was decreased in older DM1 individuals compared with foetuses. This is unlike the aberrant methylation of the FRAXA locus, which is consistent between various ages (76–78). Age-dependent methylation changes have been reported for non-disease-associated methylation, and these dynamics vary between tissues and loci and can be affected by the environment (79). Presuming that the adult DM1 individuals assessed here contained similar high levels of aberrant CpG methylation during their foetal development, as the DM1 foetuses we analysed, there must have been a loss of methylation between these two ages. Other studies in the blood DNA of DM1 individuals aged <1–62 years suggest an age-dependent loss of methylation (54). Our analysis cannot determine when or how the DM1-specific aberrant methylation is gained or lost. The apparent loss of DM1 methylation did not correlate with specific CpG sites or CTG expansion size or patient age. The decreased levels of methylation were often coincident with the increased levels of CTG length variations. It is unclear what the significance is of this apparent loss of aberrant DM1 methylation.

### DM1 methylation and CTG repeat instability

It is tempting to speculate that the absence or loss of methylation may be somehow linked to the coincident increase in inter-tissue differences in the CTG tract length. Such a relation exists in FRAXA in which evidence suggests that the presence of DNA methylation protects against contractions of expanded CGG tracts (63,80). In contrast, in many but not all adult DM1 tissues, the degree of intra-tissue somatic instability, indicated by repeats appearing as smears or multiple sized fragments, was greater in tissues retaining high levels of methylation. This might suggest that the retention of methylation correlates with increased CTG instability. Similarly, in the DM1 mice, the highest upstream methylation levels were associated with tissues displaying the largest and most heterogeneous repeat expansions (Fig. 10B and C). However, evidence from various model systems also does not present a consistent effect, as they suggest that methylation adjacent to CTG/CAG tracts can enhance or protect against repeat instability (41–44). Whether the loss of methylation is a cause of, a result of or unrelated to the increased DM1 CTG expansions cannot be concluded, but the analysis herein suggests that if such a relation exists it is complex.

The influence of methylation on CTG instability in DM1 individuals may vary between tissues. Interestingly, the cerebellum, which has the shortest repeats, was devoid of methylation. Cerebellum in DM1 and other repeat expansion diseases such as Huntington’s disease [HD (MIM 143100)], spinocerebellar ataxias 1 and 3 (MIM 164400 and MIM 109150, respectively) and dentatorubral-pallidoluysian atrophy (MIM 125370) consistently display the shortest CTG/CAG expansion size and
the most limited length heterogeneity, even compared with lymphocytes (7,19,39,81–84). Having the shortest expansion size among tissues, the cerebellum may have escaped somatic expansions and could reflect the progenitor CTG length present in the germ cell of the transmitting parent. Alternatively, the short CTG repeat in the cerebellum may even represent contractions of the progenitor size. The cerebellum may harbour trans-factors that render it less susceptible to instability (85,86). Another possibility is that the low levels of methylation in the cerebellum (87,88) may provide a cis-environment that is protective against CTG instability or conducive to contractions. It is often suggested that the progenitor CTG length present in the germ cell of the transmitting parent can be estimated as the shortest allele in the blood. However, blood is known to actively incur expansions over periods of 5–7 years (31), and hence blood may not be representative of progenitor lengths. Although we did not have access to bloods of any of our patients, Steinbach et al. (54) reported methylation in blood of DM1 patients. It is unclear whether this absence of abnormal methylation in the cerebellum indicates a dependence of CTG expansion upon methylation (or methylation loss). It would be interesting to assess the methylation status in the foetal DM1 cerebellum, as absence of methylation during early development when other tissues display high levels of methylation could support the notion that CTG instability may arise during loss of methylation, whereas tissues that escape methylation, such as the cerebellum, would be spared somatic instability. Unfortunately, foetal cerebellums were not available. Analysis of additional tissues/individuals is necessary to approximate a relation of methylation with CTG instability.

Mice versus men

Methylation of the human DM1 transgene in the DM1 mice showed similarities and differences compared with the DM1 locus in human DM1 individuals. Both showed expansion-specific methylation, tissue-specific methylation and changes in methylation levels with age in foetal/younger ages compared with adult ages. However, methylation patterns for a given tissue did not correlate between species; in humans, methylation was strongly polarized, whereas the mice showed higher methylation upstream of the CTG, but was also methylated downstream. For unknown reasons, variations between the DM1 mice and humans are evident and these must be considered.

Implications of methylation to DM1 disease

Abnormal methylation has been observed at other unstable repeat disease loci, and for some, its role in pathogenesis is known. The FRAXA, FRAXE, FRAXF, FRAX10A, FRAX11B and FRAXA16A expanded repeats are extensively methylated leading to the inactivation of the associated gene. Methylation of three CpG sites proximal to the expanded GAA repeat in FRDA patients was coincident with altered histone modifications and consistent with inactivated gene transcription (89–91). The pathogenic role is less clear in the case of the aberrant hypomethylation in the contracted D4Z4 repeats of FSHD or the hypomethylated satellite repeats in patients with immunodeficiency, centromeric instability and facial anomalies (ICF) syndrome. CpG methylation at the HD locus within (92) and 130 kb telomeric to the HTT gene (93) showed varying levels between tissues of HD patients (94,95) and their age (96). It is unknown whether methylation has a role in HD pathogenesis. Thus, for some disease loci, the role of methylation is known and for others it is less clear.

How the tissue-specific abnormal methylation upstream of the DM1-expanded CTG repeat might contribute to disease remains unknown. Although abnormal methylation is not unique to the most severe congenital form of myotonic dystrophy as previously thought (11,54), methylation upstream of the expanded CTG tract might correlate with disease onset or clinical variability. A simple correlation of our methylation results with previous DM1 gene expression levels in cells of DM1 individuals (5–7,11,16,19,97) is not obvious. We speculate that abnormal methylation might affect the expression of the toxic-CUG DMPK transcript, anti-sense-DMPK expression and/or Six-5. Such effects might vary with both the apparent age-dependent degradation of methylation and the variable CTG lengths in tissues, which could differentially affect the degree of MBNL1 protein sequestration and the severity of the resulting mis-splicing.

Finally, that many CAG/CTG repeat disease loci have proximal CTCF binding sites (9) are within large CpG islands (98), where some are known to have adjacent methylation that can vary between tissues and ages of affected individuals (94–96), and that most repeat diseases present tissue-specific vulnerability, suggests that the abnormal tissue-specific polarized CpG methylation described here at the DM1 locus might be present at other disease repeat loci.

MATERIALS AND METHODS

Transgenic mice

Transgenic mouse lines DM20-949 (20 repeats) and DM300-328 (more than 300 repeats), both harbouring a single-copy integration of ~45 kb human region that includes the DMPK gene, have been described previously (99) (Fig. 1). For studies of repeat instability and methylation at the DM1 locus, the DM20-949 and DM300-328 transgenic mice have several advantages. Both lines of transgenic mice are hemizygous and harbour single-copy integrations, which simplify the analysis of repeat stability and methylation. Also, the relatively large transgene fragment, totalling ~45 kb from the human locus and including >20 kb of sequence upstream and downstream of the CTG repeat, may insulate the repeat region from the chromatin environment that may exist at the respective integration sites. Indeed, the fragment includes three genes from the DM1 locus whose regulation in transgenic mice is similar to the human locus (100–102), suggesting that these transgenes are not subject to widespread heterochromatization. Housing and handling of mice were performed according to the French government ethical guidelines.

Human tissues

Human tissues analysed in this study are listed in Table 1. Autopsy tissues from a non-affected individual (ADN1) were
obtained snap-frozen from the National Disease Research Inter-
change. Tissues from DM1 foetuses and adult individuals were
obtained at autopsy.

DNA samples
DNA extraction from mice tissues was performed by homogen-
ization of samples, proteinase K lysis and final phenol, chloro-
form and ethanol precipitation steps. DNAs from up to eight
different tissues were collected from 4 months DM20-949
mice and 2 months DM300-328 mice. DNAs from specified
tissues were extracted from 6 months DM300-328 mice.
DNAs, from a minimum of three to eight bears similar
sizes of repeat tracts, were used for the analysis of each
DM300-328 tissue. The same DNA extraction procedure was
used to obtain genomic DNA from the various human tissue
collections available for this study (listed in Table 1).

CTG repeat analysis
Mice length of the large CTG repeat allele in the
DM300-328 mice was examined by PCR, as described in
Tomé et al. (103). Human-CTG repeat lengths were assessed
by Southern blot using a LNA probe [DIG-labelled
(CAG)7-5′-gcAgCagcAgCagCagcAgca-3′], as described pre-
viously (46). This sizing method takes advantage of the
increased electrophoretic resolution of DM1 restriction frag-
ments having a minimum of non-repetitive flanking sequences.
Non-expanded CTG allele was sized by sequencing [The Centre
for Applied Genomics (TCAG), MaRS Centre, Toronto,
Canada] of the products obtained after PCR amplification
(forward primer 409: 5′-gaagggtccttgtagccggaa-3′; reverse
primer 407: 5′-cagacgagggctgcatgcaca-3′; 66.5°C annealing).

CpG methylation analysis by bisulphite-sequencing PCR
Bisulphite treatment DNA (1–2 μg) was denatured by adding
5 μl of freshly prepared 3 M NaOH in a 50 μl total volume,
icubated at 42°C for 30 min and immediately placed on
ice. An aliquot of 510 μl of freshly prepared sodium bisulphite
(final concentration 3.3 M) and 30 μl of freshly prepared
10 μl hydroquinone was added and incubated at 55°C for
16 h. Bisulphite modification of the DNA was followed by
two consecutive cleaning and recovering steps. First,
samples were desulphonated, purified and eluted using
columns and buffers from QIAquick PCR purification kit
(Qiagen, Valencia, CA, USA). Secondly, DNA eluted in
50 μl elution buffer (10 mM Tris–Cl, pH 8.5) was denatured
with 5 μl of freshly prepared 3 M NaOH, incubated at 37°C
for 15 min, neutralized by adding 21 μl of ammonium
acetate 7.5 M (final concentration 2 M) and ethanol
precipitated. DNA was resuspended in 20–40 μl double distilled
water. If DNA concentrations were low or PCR amplification
repeatedly failed, bisulphite treatment was performed with
only 10–100 ng of DNA using the Imprint DNA Modification
kit (Sigma, Canada), optimized for low DNA quantities.
The DMPK gene region assessed is detailed in Figure 2.
DNA was amplified by hemi-nested PCR approach using
two different set of primers, ctcf1 and ctcf2 (Supplementary
Material, Table S1), to amplify upstream (5′) and downstream
(3′) from the repeat, respectively. Primers for bisulphate-
modified DNA were designed using Methyl Primer Express
Software v1.0 (Applied Biosystems, USA). An aliquot of 1–
5 μl of bisulphate-treated DNAs was amplified in 25 or
50 μl PCR reactions with the corresponding primers. Products
were resolved by running 2% agarose gel electrophoresis and
visualized by ethidium bromide staining. Detection of methyl-
ation was performed by direct PCR product sequencing as
follows: first, if necessary (i.e. non-specific PCR products
appearance), a step of gel extraction (QIAquick PCR purifi-
ication kit, Qiagen) was performed; secondly, PCR product
was cleaned (QIAquick PCR purification kit, Qiagen) and
thirdly, samples were sent routinely to the sequencing facility
of The Hospital for Sick Children (The Centre for Applied
Genomics). Additional quantification of the methylation
profiles was performed in samples with only one DM1 allele
in the genome (mouse model), by measuring in each CpG
site the cytosine height peaks in the chromatogram traces
(4Peaks software) (Supplementary Material, Fig. S4A).

CpG methylation analysis by SacII methylation-sensitive
digestion
SacII methylation-sensitive digestion (unique site 42 bases
upstream of the repeat), followed by multiplex PCR (ctcf-F
and ctcf-R encompassing the SacII site and 409 and ctcf-R
not encompassing the SacII site) (primers in Supplementary
Material, Table S1), was performed in methylated samples
(detected by bisulphite sequencing) in order to discriminate
the presence of methylation from the non-expanded DM1
alleles.

CpNpG methylation through expanded CTG alleles
To determine the methylation status of non-CpG methylation
through the extensively expanded CTG DM1 alleles, we
devised a methyl-sensitive restriction digestion assay.
Briefly, we revealed digestion by Fnu4HI to be sensitive to
cytosine methylation at CpNpG sites, and this sensitivity
combined with the LNA-Southern detection (46) was used to
assess the methylation of highly expanded CTG repeats
at the DM1 locus (details of this assay will be outlined
elsewhere).
SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We acknowledge use of tissues (sample ADN1) procured by the National Disease Research Interchange (NDRI) with support from National Institutes of Health (grant no. SU42RR006042-19). We thank Dr V.L. Funanage for providing DMPK491 and DMR8993 cell lines. We thank Dr M. Baiget for providing the homozygous DM1 samples.

Conflict of Interest statement. The authors declare no conflict of interest.

FUNDING

This work was supported in the Pearson laboratory by the Canadian Institutes of Health Research, the Muscular Dystrophy Association and post-doctoral fellowships from the Cell Science Research Foundation and the Uehara Memorial Foundation and postdoctoral fellowships from the Cell Science Research Foundation and the Uehara Memorial Foundation (A.L.C.). Work in the Thornton laboratory is supported by the University of Rochester Paul Wellstone Muscular Dystrophy Cooperative Research Center with support from the NIH (grant no. U54NS48843) and the Muscular Dystrophy Association and postdoctoral fellowships from the Cell Science Research Foundation and the Uehara Memorial Foundation (M.N.). Work in the Gourdon laboratory is supported by the Institut National de la Santé et de la Recherche Médicale, the Association Française contre les Myopathies, the Agence Nationale de la Recherche, and a PhD grant from the ‘Ministère Français de la Recherche et de la Technologie’ (S.T.).

REFERENCES


